So basic gaaa India lo cases surging ki covaxin eee reason Ani kotha theory 

 

 March 30, the Brazilian drug regulator, Anvisa, published a report listing a litany of quality problems with Bharat Biotech’s manufacturing plant for its inactivated COVID vaccine, Covaxin. These problems included insufficient measures to ensure that the SARS-COV-2 virus was completely killed and that the vaccine was free of microbial contamination. The report also talked about possible variations in Covaxin’s potency from one dose to another.

 

 

https://www.google.com/amp/s/www.thequint.com/amp/story/coronavirus/explained-why-is-cdsco-silent-on-brazils-report-on-bharat-biotech-plant

10 minutes ago, sri_india said:

So basic gaaa India lo cases surging ki covaxin eee reason Ani kotha theory 

 

 March 30, the Brazilian drug regulator, Anvisa, published a report listing a litany of quality problems with Bharat Biotech’s manufacturing plant for its inactivated COVID vaccine, Covaxin. These problems included insufficient measures to ensure that the SARS-COV-2 virus was completely killed and that the vaccine was free of microbial contamination. The report also talked about possible variations in Covaxin’s potency from one dose to another.

 

 

https://www.google.com/amp/s/www.thequint.com/amp/story/coronavirus/explained-why-is-cdsco-silent-on-brazils-report-on-bharat-biotech-plant

moolige nakka meeda tatipandu paddattu undi ga!

13 minutes ago, sri_india said:

So basic gaaa India lo cases surging ki covaxin eee reason Ani kotha theory 

 

 March 30, the Brazilian drug regulator, Anvisa, published a report listing a litany of quality problems with Bharat Biotech’s manufacturing plant for its inactivated COVID vaccine, Covaxin. These problems included insufficient measures to ensure that the SARS-COV-2 virus was completely killed and that the vaccine was free of microbial contamination. The report also talked about possible variations in Covaxin’s potency from one dose to another.

 

 

https://www.google.com/amp/s/www.thequint.com/amp/story/coronavirus/explained-why-is-cdsco-silent-on-brazils-report-on-bharat-biotech-plant

Chinaku ammudupoina Brazil antunna @ZoomNaidu

russia russia annaru ga adi vesukondi va india lo unnollu

11 minutes ago, 8pm said:

moolige nakka meeda tatipandu paddattu undi ga!

Many countries 2nd wave ni control chesthunayi .... But India failed big time Ani janalu okatee racha

CBN setup chesina barath biotech meeda ne inni abandalu vestara

35 minutes ago, chandrabhai7 said:

CBN setup chesina barath biotech meeda ne inni abandalu vestara

Velli CBN m*dda kuduv

1 hour ago, sri_india said:

So basic gaaa India lo cases surging ki covaxin eee reason Ani kotha theory 

 

 March 30, the Brazilian drug regulator, Anvisa, published a report listing a litany of quality problems with Bharat Biotech’s manufacturing plant for its inactivated COVID vaccine, Covaxin. These problems included insufficient measures to ensure that the SARS-COV-2 virus was completely killed and that the vaccine was free of microbial contamination. The report also talked about possible variations in Covaxin’s potency from one dose to another.

 

 

https://www.google.com/amp/s/www.thequint.com/amp/story/coronavirus/explained-why-is-cdsco-silent-on-brazils-report-on-bharat-biotech-plant

biggest drawback

engineering ni champesaru by all levels desam lo

eppatiki marathadho kooda telidhu

1 hour ago, sri_india said:

So basic gaaa India lo cases surging ki covaxin eee reason Ani kotha theory 

 

 March 30, the Brazilian drug regulator, Anvisa, published a report listing a litany of quality problems with Bharat Biotech’s manufacturing plant for its inactivated COVID vaccine, Covaxin. These problems included insufficient measures to ensure that the SARS-COV-2 virus was completely killed and that the vaccine was free of microbial contamination. The report also talked about possible variations in Covaxin’s potency from one dose to another.

 

 

https://www.google.com/amp/s/www.thequint.com/amp/story/coronavirus/explained-why-is-cdsco-silent-on-brazils-report-on-bharat-biotech-plant

 

india lo unna double-mutant aithe covaxin theeskunte  protection untundi ani news lo ochindi

13 minutes ago, guduraju said:

Velli CBN m*dda kuduv

enti ee avesam

3 minutes ago, Pitta said:

36 minutes ago, perugu_vada said:

india lo unna double-mutant aithe covaxin theeskunte  protection untundi ani news lo ochindi

Yevadu confirm chesindu idi chesina tests 10000-15000 mandi mida data peer review kuda cheyaledu agamegala midha approval ichi pad thenginru. 

1 hour ago, sri_india said:

So basic gaaa India lo cases surging ki covaxin eee reason Ani kotha theory 

 

 March 30, the Brazilian drug regulator, Anvisa, published a report listing a litany of quality problems with Bharat Biotech’s manufacturing plant for its inactivated COVID vaccine, Covaxin. These problems included insufficient measures to ensure that the SARS-COV-2 virus was completely killed and that the vaccine was free of microbial contamination. The report also talked about possible variations in Covaxin’s potency from one dose to another.

 

 

https://www.google.com/amp/s/www.thequint.com/amp/story/coronavirus/explained-why-is-cdsco-silent-on-brazils-report-on-bharat-biotech-plant

QUINT... chalu..